Effectiveness of tamsulosin hydrochloride and its mechanism in improving nocturia associated with lower urinary tract symptoms/benign prostatic hyperplasia

Neurourology and Urodynamics

Volumn 29, Issue 7, 2010, Pages 1276-1281

  Yoshida, Masaki ^a   Inadome, Akito ^a   Masunaga, Koichi ^a   Nagata, Takashi ^a   Yoshiyasu, Takashi ^b  

^a KUMAMOTO UNIVERSITY   (Japan)

^b ASTELLAS PHARMA INC   (Japan)

Author keywords

Alpha 1 adrenoreceptor blocker; Benign prostatic hyperplasia; Frequency volume chart (FVC); Lower urinary tract symptoms; Mechanism; Nocturia

Indexed keywords

NAFTOPIDIL; TAMSULOSIN;

ARTICLE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; NOCTURIA; POLYURIA; POSTVOID RESIDUAL URINE VOLUME; PROSTATE HYPERTROPHY; QUALITY OF LIFE; SLEEP; TREATMENT DURATION; URINARY FREQUENCY; URINE FLOW RATE; UROFLOWMETRY;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; AGED; HUMANS; JAPAN; MALE; MIDDLE AGED; NOCTURIA; PRODUCT SURVEILLANCE, POSTMARKETING; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; SLEEP; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME; URINARY INCONTINENCE; URODYNAMICS;

EID: 77956846937     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.20872     Document Type: Article

References (25)

1. Wolters R, Wensing M, van Weel C, et al. Lower urinary tract symptoms: Social influence is more important than symptoms in seeking medical care. BJU Int 2002;90:655-661
2. McVary KT. BPH: Epidemiology and comorbidities. Am J Manag Care 2006; 12:S122-8.
3. Peters TJ, Donovan JL, Kay HE, et al. The International Continence Society benign prostatic hyperplasia study: The bothersomeness of urinary symptoms. J Urol 1997;157:885-889
4. A comparison of quality of life with patient reported symptoms and objective findings in men with benign prostatic hyperplasia. The Department of Veterans Affairs Cooperative Study of transurethral resection for benign prostatic hyperplasia. J Urol 1993;150:1696-1700
5. Abrams P. Nocturia: The major problem in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (LUTS/BPO). Eur Urol Suppl 2005;3:8-16.
6. Fultz NH, Herzog AR. Epidemiology of urinary symptoms in the geriatric population. Urol Clin North Am 1996;23:1-10.
7. Blanker MH, Bohnen AM, Groeneveld FP, et al. Normal voiding patterns and determinants of increased diurnal and nocturnal voiding frequency in elderly men. J Urol 2000;164:1201-1205
8. Weiss JP, Blaivas JG, Stember DS, et al.. Nocturia in adults: Etiology and classification. Neurourol Urodyn 1998;17:467-472
9. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1:Diagnosis and treatment recommendations. J Urol 2003;170:530-547
10. Tsujii T. Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia:A short-term open, randomized multicenter study. Int J Urol 2000;7:199-205.
11. Narayan P, Evans CP, Moon T. Long-termsafety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 2003;170:498-502.
12. Yoshida M, Yoshiyasu T. Efficacy of tamsulosin hydrochloride and mechanism of the onset of action in patients with nocturia associated with benign prostatic hyperplasia. Jpn J Urol Surg 2008;21: 1211-1220
13. Horiuchi K, Tsuboi N, Hattori T, et al. The short-term effects of tamsulosin in Japanese men with benign prostatic hyperplasia. J Nippon Med Sch 1999; 66:382-387
14. Yoshida M, Sugiyama Y, Masunaga K, et al. Effect of tamsulosin hydrochloride on lower urinary tract symptoms and quality of life in patients with benign prostatic hyperplasia. Evaluation using bother score. Drugs Today 2007;43:1-7.
15. Yoshimura K, Ohara H, Ichioka K, et al. Nocturia and benign prostatic hyperplasia. Urology 2003;61:786-790
16. Momose H, Hosokawa Y, Kishino T, et al. Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia. Drugs Today 2007;43:1-10.
17. Yap TL, Cromwell DA, Brown C, et al. The relationship between objective frequency-volume chart data and the I-PSS in men with lower urinary tract symptoms. Eur Urol 2007;52:811-818 (Pubitemid 47126134)
18. Yokoyama O, Yusup A, Oyama N, et al. Improvement in bladder storage function by tamsulosin depends on suppression of C-fiber urethral afferent activity in rats. J Urol 2007;177:771-775
19. Chartier-Kastler E, Chapple CR. LUTS/BPH in clinical practice: The importance of nocturia and quality of sleep. Eur Urol Suppl 2006;2:3-8 (Pubitemid 44423029)
20. Chartier-Kastler E, Tubaro A. The measurement of nocturia and its impact on quality of sleep and quality of life in LUTS/BPH. Eur Urol Suppl 2006;5: 3-11. (Pubitemid 43003497)
21. Djavan B, Milani S, Davies J, et al. The impact of tamsulosin oral controlled absorption system (OCAS) on nocturia and the quality of sleep: Preliminary results of a pilot study. Eur Urol Suppl 2005;4: 61-68
22. Abrams P, Mattiasson A, van Kerrebroeck P, et al. Nocturnal polyuria is a key factor in nocturia. Neurourol Urodyn 2004;23:466-467
23. Sakakibara R, Uchiyama T, Liu Z, et al. Nocturnal polyuria with abnormal circadian rhythm of plasma arginine vasopressin in post-stroke patients. Intern Med 2005;44:281-284
24. Matthiesen TB, Rittig S, Nørgaard JP, et al. Nocturnal polyuria and natriuresis in male patients with nocturia and lower urinary tract symptoms. J Urol 1996;156:1292-1299
25. Liu RY, Unmehopa UA, Zhou JN, et al. Glucocorticoids suppress vasopressin gene expression in human suprachiasmatic nucleus. J Steroid Biochem Mol Biol 2006;98:248-253